AML patients receive cancer drug DCP-001
December 3, 2018DCprime (spin-off VUmc) announces first patient dosed in phase 2 ADVANCE-II study with DCP-001 in patients with Acute Myeloid Leukemia. This administration marks the official start of the phase 2 study in the ADVANCE-II study. A total of 20 patients with acute myeloid leukemia (AML), a rare form of leukemia, participate in this study. A recently completed phase I study showed that the cancer drug DCP-001, a vaccine based on dendritic cells, is generally safe and capable of triggering an anti-cancer immune response in patients with AML.
Read here the full press release.
More news
Inspire your students with Amsterdam entrepreneurship cases
Tuesday 23 April two new entrepreneurship teaching cases have been launched: The Next Web and Radically Open. By involving examples about inspiring Amsterdam entrepreneurs in education, students get inspiring examples from their immediate environment. The cases can be used at any level, but are especially suitable for late Bachelor and Master level entrepreneurship courses at […]
News
Is sweat the ideal outcome for diabetics?
Meerdere keren per dag bloedprikken om je bloedsuiker te bepalen. Het is voor diabetici dagelijkse kost. Maar als het aan dr. Elizabeth von Hauff (GlucoEasy, Vrije Universiteit Amsterdam) ligt, hoeft dat in de toekomst niet meer. Ze ontwikkelt een nieuwe meettechniek die verder gaat dan biochemische sensoren. Hoe ontstond het idee voor dit project? “Dat […]
News
KTO Masterclass in CES Unveiled at Beurs van Berlage
On the 17th of October, 70 KTO colleagues from the different universities of the Netherlands came together to participate in the annual KTO Masterclass as part of CES Unveiled at the Beurs van Berlage, hosted by IXA. Gigi Wang kicked of the day with an energizing presentation. Gigi runs the MG-Team, which delivers global entrepreneurship […]
News